BiotechTube

CSJ137 + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia, Iron-Deficiency

Conditions

Anemia, Iron-Deficiency

Trial Timeline

Sep 22, 2015 → May 13, 2020

NCT ID
NCT02570854

About CSJ137 + Placebo

CSJ137 + Placebo is a phase 1 stage product being developed by Novartis for Anemia, Iron-Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02570854. Target conditions include Anemia, Iron-Deficiency.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02570854Phase 1Completed

Competing Products

20 competing products in Anemia, Iron-Deficiency

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
84
KER-047Keros TherapeuticsPhase 2
44
LY2787106Eli LillyPhase 1
33
R744 + R744Chugai PharmaceuticalPhase 3
77
epoetin beta + placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
darbepoetin alfaAmgenPhase 3
76
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaPhase 1
33
RoxadustatAstellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 1
33
Roxadustat + PlaceboAstellas PharmaPhase 3
77
RoxadustatAstellas PharmaPre-clinical
23
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85